

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the application of: Hans P. Albrecht, *et al.*

Serial No.: 09/284,424

Filed: April 9, 1999 (CPA filed October 23, 2001)

For: *ASPARTATE ESTER INHIBITORS OF INTERLEUKIN-1 β CONVERTING ENZYME*

Attorney Docket No.: BBI-5037CPUSCPA

Group Art Unit: 1623

Examiner: Leigh C. Maier

Commissioner for Patents
Washington, D.C. 20231

<u>Certificate of Facsimile Transmission</u>	
I hereby certify that this correspondence is being facsimile transmitted to the Commissioner for Patents, Washington, DC 20231 on:	
<u>July 30, 2002</u>	By: <u>Peter C. Lauro</u>
Date of Signature and of Facsimile Transmission	Peter C. Lauro, Esq. Reg. No. 32,360 Attorney for Applicants

AMENDMENT AND RESPONSE

Dear Sir:

This application is a continued prosecution application ("CPA") pursuant to 37 C.F.R. § 1.53(d). In further response to the final Office Action (Paper No. 12) dated February 22, 2001, please amend the application as follows:

IN THE SPECIFICATION:

NE
Please delete page 76 and insert therefor replacement page 76 attached hereto (to change "-ethylsulfanylamino)" to "-ethylsulfonylamino)" in the name of the title compound of Example 2e).